400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / MAPK/ERK Pathway / p38 MAPK / Talmapimod/他匹莫德
CAS No.: 309913-83-5
Synonyms: SCIO-469;SD-282;SCI-O282
SCIO-469 is a selective ATP-competitive p38 inhibitor with IC50 of 9 nM for p38α in vitro, about 10-fold selectivity for p38α over p38β, and at least 2000-fold selectivity for p38α over an in vitro panel of 20 other kinases, including other MAK kinases.
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT00089921 | Arthritis, Rheumatoid | Phase 2 | Completed | - | - |
NCT00113893 | Bone Marrow Diseases ... more >> Myelodysplastic Syndromes Hematologic Diseases Bone Marrow Neoplasms Collapse << | Phase 2 | Completed | - | - |
NCT00087867 | Multiple Myeloma | Phase 2 | Completed | - | - |
实验方案
技术信息
CAS号 | 309913-83-5 | 储存条件 |
|
|
分子式 | C27H30ClFN4O3 | 运输 | 蓝冰 | |
分子量 | 513.00 | 别名 | SCIO-469;SD-282;SCI-O282;他匹莫德 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT00089921 | Arthritis, Rheumatoid | Phase 2 | Completed | - | - |
NCT00113893 | Bone Marrow Diseases ... more >> Myelodysplastic Syndromes Hematologic Diseases Bone Marrow Neoplasms Collapse << | Phase 2 | Completed | - | - |
NCT00087867 | Multiple Myeloma | Phase 2 | Completed | - | - |
NCT00508768 | Rheumatoid Arthritis | Phase 1 | Completed | - | - |
NCT00043732 | Rheumatoid Arthritis | Phase 2 | Completed | - | - |
NCT00095680 | Multiple Myeloma | Phase 2 | Completed | - | - |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网